BackIntensity Therapeutics Overview
Intensity Therapeutics Inc

Intensity Therapeutics Discounted Cash Flow

DCF fair value estimate for Intensity Therapeutics: $0.87.

Get informed when a big investor buys or sells

+ Follow

Fair Value

$0.87

Current Fair Value

$0.87
↓ 79.0% Downside

Overvalued by 79.0% based on the discounted cash flow analysis.

Average Upside/Downside (Comparison Companies)

Loading

Fair Value vs. Stock Price History

Loading

Upside/Downside History

Loading

Upside/Downside Comparison

Loading

Intensity Therapeutics (INTS) FAQ

The latest DCF fair value for INTS is $0.87. Investors often review this figure alongside Intensity Therapeutics's historical trend and sector peers before judging valuation or financial health.

A DCF fair value of $0.87 for Intensity Therapeutics suggests the stock may be overvalued by roughly 79.0% at today's price. That does not mean the market is 'wrong'; it means the model's cash-flow assumptions imply a different intrinsic value. Stress-test the estimate by comparing it with historical valuation ranges and peer multiples.

After noting INTS's DCF fair value ($0.87), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.